Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.3K Sell
123
-12
-9% -$2.62K ﹤0.01% 1869
2026
Q2
$26.4K Buy
135
+14
+12% +$2.9K ﹤0.01% 1878
2026
Q1
$27.2K Hold
121
– – ﹤0.01% 1577
2025
Q4
$29.2K Sell
121
-766
-86% -$196K ﹤0.01% 1581
2025
Q3
$243K Hold
887
– – 0.02% 608
2025
Q2
$229K Buy
887
+766
+633% +$183K 0.02% 588
2025
Q1
$27.1K Sell
121
-642
-84% -$150K ﹤0.01% 1344
2024
Q4
$175K Buy
763
+648
+563% +$156K 0.01% 663
2024
Q3
$28.1K Buy
+115
New +$25.7K ﹤0.01% 1308

Other funds holding RMD

BFC Planning's RMD Position: Q3 2026 in Review

BFC Planning reduced its ResMed (RMD) stake by 8.9% in Q3 2026, selling an estimated $2.62K and leaving 123 shares worth $27.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1869.

BFC Planning first reported a position in RMD in Q3 2024 and has held it in 9 quarters since. The position peaked at $243K in Q3 2025. 778 funds tracked by Wall St. Rank hold RMD as of Q3 2026.

  • BFC Planning held 123 shares of ResMed worth $27.3K as of Q3 2026.
  • BFC Planning sold 12 ResMed shares in Q3 2026, an estimated $2.62K.
  • ResMed made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1869 holding.
  • BFC Planning first reported a position in ResMed in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's ResMed position peaked at $243K in Q3 2025.
  • 778 funds tracked by Wall St. Rank held ResMed as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.